Equities & Corporate Finance
US drug regulators reject ecstasy as mental health treatment
Expert analysis for corporate strategists
Want a deeper look?
Explore our recommended subscriptions
We’ve got you covered
FT Equity Market
Reports Understand equity markets and corporate strategies with FT analysis.
CEO & Investor Insights
Exclusive insights from industry leaders and financial experts including Gillian Tett and John Gapper.
Asset Management newsletter
The inside story on the movers and shakers behind a multi-trillion dollar industry.
Due Diligence Newsletter
The top stories from corporate finance and private equity, including detailed analysis of the dealmakers driving the news.
FT Equity Market
Reports Understand equity markets and corporate strategies with FT analysis.
CEO & Investor Insights
Exclusive insights from industry leaders and financial experts including Gillian Tett and John Gapper.
Asset Management newsletter
The inside story on the movers and shakers behind a multi-trillion dollar industry.
Due Diligence Newsletter
The top stories from corporate finance and private equity, including detailed analysis of the dealmakers driving the news.
Explore more offers.
Standard Digital
Essential digital access to quality FT journalism on any device. Pay a year upfront and save 20%.
Premium Digital
Complete digital access to quality FT journalism with expert analysis from industry leaders. Pay a year upfront and save 20%.
Print + Premium Digital
Complete digital access to quality analysis and expert insights, complemented with our award-winning Weekend Print edition.
Terms & Conditions apply
Explore our full range of subscriptions.
Why the FT?
See why over a million readers pay to read the Financial Times.
